stockportfolio.pro
Stocks / HALO vs QGEN
HALO vs QGEN
Halozyme Therapeutics, Inc. and Qiagen N.V. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Halozyme Therapeutics, Inc. (HALO) | Qiagen N.V. (QGEN) | |
|---|---|---|
| Market cap | $8.4B | $7.6B |
| Revenue (latest FY) | $1.40B | $2.09B |
| Net income (latest FY) | $316.89M | $424.88M |
| Revenue growth (5y CAGR) | 39.2% | -0.8% |
| Net margin | 22.7% | 20.3% |
| Return on equity | 649.2% | 11.2% |
| P/E ratio | 24.9 | 18.8 |
| Dividend yield | — | 0.9% |
| Profitable years (of last 10) | 7 | 4 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HALO — free Open QGEN — freeFrequently asked questions
Which is bigger, HALO or QGEN?
Halozyme Therapeutics, Inc. is larger by market capitalization — $8.4B versus $7.6B.
Which grows faster, HALO or QGEN?
Over the last five fiscal years, Halozyme Therapeutics, Inc. grew revenue faster — 39.2%/yr versus -0.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.